These findings provide rationale for defining the exact mechanisms of PD-L1 signaling and may be an explanation as to why PD-L1 antibodies may not be as effective as PD-1 antibodies in a cancer setting (30) but may be a potential target for autoimmune inflammatory disorders like psoriasis where DC migration is detrimental (31). Here, PDCD1 is linked to cancer.